• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0

Recombinant Human FGFR4 protein (C-rFc)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

rFc Tag

Activity

not tested

Cat no : Eg3510

Validation Data Gallery

Product Information

Purity >90 %, SDS-PAGE
Endotoxin <1.0 EU/μg protein, LAL method
Activity 
Not tested
Expression HEK293-derived Human FGFR4 protein Leu22-Asp369 (Accession# P22455-1) with a rabbit IgG Fc tag at the C-terminus.
GeneID 2264
Accession P22455-1
PredictedSize 64.8 kDa
SDS-PAGE
Formulation Lyophilized from sterile PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage Conditions
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

Fibroblast growth factor receptor 4 (FGFR4) is a member of a highly conserved tyrosine kinase family, along with FGFR1-3. This family consists of an intracellular tyrosine kinase domain, a single transmembrane domain, and extracellular ligand-binding domains. FGFR4 is the predominant FGFR isoform present in human hepatocytes. FGFR4 has been proposed to play a role in the observed induction of hepatocyte proliferation and carcinogenesis by FGF19; however, contradicting evidence proposing a protective role for FGFR4 in suppressing hepatoma progression has also been proposed. While the role of FGFR4 in cancer remains to be fully elucidated, several findings suggest that this receptor may be an important player in Hepatocellular carcinoma (HCC) development and/or progression.

References:

1. Levine, Kevin M et al. Pharmacology & therapeutics vol. 214 (2020): 107590.
2. Wu, Xinle et al. The Journal of biological chemistry vol. 285,8 (2010): 5165-70.
3. Kan, M et al. The Journal of biological chemistry vol. 274,22 (1999): 15947-52.